2025.11.20
*Notice* Revolutionizing Human Brain Disease Treatment! Yamaguchi University-Spun Startup ADDVEMO Launches in Earnest
To pioneer a new era in brain disease treatment, ADDVEMO Inc., a startup born from Yamaguchi University on October 7, 2024, announced the full-scale launch of its business centered on its proprietary human blood-brain barrier (BBB) model kit, the “cuBe kit.”
Professor Yukio Takeshita and colleagues from the Graduate School of Medicine and The Research Institute for Cell Design and Medical Science at Yamaguchi University developed the cuBe kit, the world’s first high-performance human brain vascular model kit featuring a three-layer structure, as a result of years of original research. Based on these research achievements, Professor Takeo Takeshita (Department of Neurotherapeutics) and Assistant Professor Naoomi Tominaga (Clinical Laboratory Sciences) established ADDVEMO Inc. as a Yamaguchi University spin-off startup in October last year to accelerate brain drug development. With funding from Ube City, they held a joint press conference at Ube City Hall with relevant parties in attendance to announce the full-scale launch of a project aiming to establish Ube City as a hub for brain drug development and manufacturing.
At the press conference, Professor Takeshita, who is also the CEO of ADDVEMO Co., Ltd., explained the project’s business plan. This includes manufacturing and selling the cuBe kit, conducting contract research with pharmaceutical companies, and developing brain-targeted drugs for dementia using the cuBe kit in-house. He expressed his aspiration that these initiatives will ultimately contribute to industrial development in Ube City through brain-targeted drug development and help realize a world where diseases, including brain disorders, can be cured, thereby achieving a Ube-style regional revitalization.
